GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts
GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous X-ray and ultrasound solutions
GE HealthCare expands invasive cardiology solutions portfolio with AltiX AI.i for elevated experience in catheterization lab and electrophysiology procedures
GE HealthCare Technologies Inc. (NASDAQ: GEHC) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $100.00 price target on the stock, up previously from $85.00.
GE HealthCare Advances Its Cloud Strategy by Unveiling the Genesis Portfolio to Improve Speed of Digital Innovation Adoption